OakChart

NeOnc Technologies Holdings Inc

NTHIHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:35 PM ET

4.54+0.17 (3.89%)
2026-11-11 21:35 CET
Market cap
126.08 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-45.86 USD m
Free cash flow, TTM
-20.44 USD m
EPS diluted, TTM
-1.95
P/E
-
Compare

Price

NTHI against its 20, 50 and 200-day averages
2050200miss
4.006.008.00553K1.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26NTHIclose 4.5420-day 3.2050-day 3.30200-day 5.264.5452w low

62.2% under the 52-week high of 12.00 on 12 Nov 2025. 52-week low 2.50 on 9 Oct 2026. Last 15 sessions, 73.2% high to low

Volume 1.30× normal · the line is the 50-bar volume average

Profile

NTHI
52-week range, 21% of the way up
2.5012.00

NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company. It develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company was founded in 2008 and is headquartered in Calabasas, CA.

Employees5
IPOMar 26, 2025
Beta0.56
ATR, 14d0.38
Rel volume1.30
Short float34.87%
Insider own90.84%
Inst own10.92%

Snapshot

6 groups

Valuation

Index-
Market Cap130.98M
Enterprise Value125.12M
Income-45.86M
Sales0.00M
Book/sh-0.47
Cash/sh0.21
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees5
IPOMar 26, 2025

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C21.23
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.34
Current Ratio0.34
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-1.95
EPS next Y-0.99
EPS next Q-0.26
EPS this Y58.06%
EPS next Y26.08%
EPS next 5Y34.60%
EPS past 3/5Y-176.88% -109.20%
Sales past 3/5Y25.98% -
EPS Y/Y TTM33.59%
Sales Y/Y TTM-100.00%
EPS Q/Q37.10%
Sales Q/Q-
EarningsNov 05 BMO
EPS/Sales Surpr.-12.90% -

Ownership

Insider Own90.84%
Insider Trans0.97%
Inst Own10.92%
Inst Trans1.86%
ROA-642.77%
ROE-
ROIC-
Gross Margin-
Oper. Margin-
Profit Margin-
SMA2042.01%
SMA5037.63%
SMA200-13.75%
Trades-

Technical

Shs Outstand27.77M
Shs Float2.64M
Short Float34.87%
Short Ratio4.17
Short Interest0.92M
52W High12.00 -62.17%
52W Low2.50 81.53%
Volatility13.66% 10.92%
ATR (14)0.38
RSI (14)74.93
Beta0.56
Rel Volume1.30
Avg Volume220.95K
Volume270,594

Performance

Perf Week43.22%
Perf Month74.95%
Perf Quarter41.43%
Perf Half Y-16.24%
Perf YTD-45.10%
Perf Year-60.25%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.00
Target Price17.00
Prev Close4.37
Price4.54
Change %3.89%

Analyst ratings

latest 4 of 4
DateActionAnalystRating changeTargetImplied
Sep 24, 2026InitiatedRRoth CapitalBuy$20+340.5%
May 19, 2026InitiatedAAlliance Global PartnersBuy$13+186.3%
May 18, 2026InitiatedMMaxim GroupBuy$20+340.5%
Apr 24, 2026InitiatedBBTIG ResearchBuy$15+230.4%

Peers

Mkt cap
TickerCompanyMkt cap
KZIAKazia Therapeutics Limited ADR84.01M
CNSPCns Pharmaceuticals Inc5.32M
MBIOMustang Bio Inc3.25M
NUVBNuvation Bio Inc1.54B
CLRBCellectar Biosciences Inc11.25M
MBRXMoleculin Biotech Inc8.63M
ANIXAnixa Biosciences Inc98.04M
CRDFCardiff Oncology Inc59.46M
NVCRNovoCure Ltd1.40B
INOInovio Pharmaceuticals Inc146.31M

Insider trading

latest 14 of 29
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Heshmatpour Amir FCEO, PresidentNov 09 '26Buy3.8610,00038,6003,263,000Nov 09 07:00 PM
Heshmatpour Amir FCEO, PresidentNov 06 '26Buy3.3940,000135,5003,253,000Nov 09 06:00 AM
Heshmatpour Amir FCEO, PresidentNov 05 '26Buy3.1730,00095,0103,213,000Nov 09 06:00 AM
Heshmatpour Amir FCEO, PresidentSep 15 '26Buy3.3035,000115,3953,183,000Sep 15 08:47 PM
Heshmatpour Amir FCEO, PresidentSep 14 '26Buy3.9615,00059,4003,148,000Sep 15 08:47 PM
CHEN THOMAS CCEOSep 11 '26Buy3.605,55620,00219,261Sep 15 08:45 PM
CHEN THOMAS CCEOSep 14 '26Buy3.815,24219,99824,503Sep 15 08:45 PM
GARNETT KEITHLYCFOSep 14 '26Buy3.892571,001242,357Sep 15 08:44 PM
KEITHLY GARNETTOfficerSep 15 '26Proposed Sale3.785,00018,900Sep 15 04:43 PM
Heshmatpour Amir FCEO, PresidentSep 11 '26Buy3.6737,000135,6203,133,000Sep 14 06:00 AM
CHEN THOMAS CCEOAug 18 '26Buy5.4912,75769,99813,705Aug 20 09:15 PM
CHEN THOMAS CCEOAug 14 '26Buy3.8533,787130,002581,059Aug 18 04:13 PM
CHEN THOMAS CCEOAug 17 '26Buy4.042,4729,998583,531Aug 18 04:13 PM
Heshmatpour Amir FCEO, PresidentAug 18 '26Buy5.549,00049,8603,096,000Aug 18 02:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 100
  • NeOnc Technologies Granted FDA Type B End-of-Phase Meeting to Discuss Potential Accelerated Approval Pathway and Phase 3 Confirmatory Trial for Intranasal NEO100 (GlobeNewswire)
  • FDA Meeting Could Put NeOnc's NEO100 Experimental Brain Cancer Drug on Faster Track (GlobeNewswire)
  • NeOnc CEO Amir Heshmatpour Adds 80,000 Shares in Open-Market Purchases (GlobeNewswire) +16.84%
  • NeOnc CEO Adds Another 70,000 Shares as Insider Buying Continues (GlobeNewswire) +7.16%
  • NeOnc Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress (GlobeNewswire)
  • NeOnc Is Putting Two Brain Cancer Programs on the Global Stage (GlobeNewswire) -5.83%
  • NeOnc Technologies to Present Data from Its NEO100 and NEO212 Programs at the 31st Annual Meeting of the Society for Neuro-Oncology (GlobeNewswire)
  • NeOnc's Ambitious Brain Cancer Plans are Setting the Stage (GlobeNewswire)
  • NeOnc Targets Major Brain Cancer Trial Expansion with 500 Patients Across 30 Hospitals in Three Countries (GlobeNewswire) -13.76%
  • NeOnc Breaks Through Key Levels, as Brain-Cancer Stock's Catalysts Continue (GlobeNewswire) +10.85%
  • NeOnc Heads to Fox Business as Brain Cancer Milestones Put Its Mission in the Spotlight (GlobeNewswire)
  • NeOnc Technologies to Be Featured on Health Uncensored with Dr. Drew to Discuss Reaching Brain Tumors Without Surgery or Systemic Chemotherapy (GlobeNewswire)
  • NeOnc's Brain Cancer Efforts Bring Hope as FDA Meeting Approaches (Newsfile)
  • NeOnc Deepens Abu Dhabi Research Ties as Its Brain Cancer Story Moves Forward (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.280-0.248-0.2150.000.005
2026Q22026-08-10-0.580-0.117-0.5770.000.003
2026Q12026-05-18-0.380-0.219-0.3790.00-2
2025Q42026-04-01-0.464-0.370-0.716--1
2025Q32025-12-03-0.450--0.449---
2026Q4---0.256--0.005
2027Q1---0.240--0.004
2027Q2---0.260--0.004
2027Q3---0.248--0.004
2027Q4---0.263--0.004
2028Q1---0.124---1
2028Q2---0.200---1
2028Q3---0.117---1
2028Q4---0.174---1
2029Q1---0.126---1
2029Q2---0.203---1

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-3.200-3.140-3.2000.040.00
2026FY--1.342--0.00
2027FY--0.992--0.00
2028FY--0.895---
2029FY--0.301--42.06
2030FY-0.765--115.29

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-052000.000.000.00
2026Q4S2026-09-232000.000.000.00
2026Q4S2026-08-101000.000.000.00
2026Q4S2026-05-181000.000.000.00
2026Q4R2026-11-05220-0.16-0.17-0.14
2026Q4R2026-10-27210-0.17-0.17-0.16
2026Q4R2026-09-04211-0.17-0.17-0.16
2026Q4R2026-08-26201-0.17-0.18-0.16
2026Q4R2026-08-13301-0.16-0.18-0.15
2026Q4R2026-08-10300-0.15-0.18-0.13
2026Q4R2026-08-05300-0.15-0.18-0.13
2026Q4R2026-05-22310-0.15-0.18-0.13
2026Q4R2026-05-18300-0.16-0.19-0.13
2026Q4R2026-04-22100-0.19-0.19-0.19

Estimate history

EPS, annual-0.15-0.135-0.661-0.527-2.866-1.9539
Period20212022202320242025TTM
EPS, quarterly-0.122-0.1-2.096-0.299-0.449-0.716-0.379-0.577-0.282
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00.020.070.0830.040
Period20212022202320242025TTM
Sales, quarterly00.020.04000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual22.5622.5622.5622.5621.68827.771
Period20212022202320242025MRQ
Shares, quarterly18.09122.5619.02719.02719.47421.68824.12824.85427.771
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Total Revenue0.000.040.080.070.020.00
Cost of Goods Sold Incl. D&A0.080.04---0.00
Gross Profit-0.080.00---0.00
Selling, General and Administrative Excl. Other40.5758.247.188.172.863.27
Research and Development6.493.643.051.531.160.67
Other Operating Expense0.000.000.000.000.000.00
Operating Income-40.66-58.24-7.10-8.10-2.84-3.27
Interest Expense3.433.622.702.720.200.11
Unusual Expense-1.290.692.114.100.01-0.01
Net Income Before Taxes-43.02-62.15-11.90-14.92-3.05-3.38
Income Taxes0.000.000.000.000.000.00
Consolidated Net Income-43.02-62.15-11.90-14.92-3.05-3.38
Net Income From Continuing Operations-43.02-62.15-11.90-14.92-3.05-3.38
Net Income-45.86-62.15-11.90-14.92-3.05-3.38
EPS (Recurring)-1.81-2.84-0.46-0.53-0.13-0.15
EPS (Basic, Before Extraordinaries)-1.95-2.87-0.53-0.66-0.14-0.15
EPS (Diluted)-1.95-2.87-0.53-0.66-0.14-0.15
EBITDA-40.57-58.20-7.10-8.10-2.84-3.27
Non-Operating Income (Expense)-0.220.400.020.000.000.00
Other After Tax Adjustments0.000.000.000.000.000.00
Stock Option Compensation Expense18.2435.56-0.001.292.22
Price To Sales Ratio-4,485.10----
Gross Margin-8.82----
Operating Margin--145,637.52-8,555.75-11,492.25-14,188.02-
Net Margin--155,404.38-14,335.50-21,176.05-15,233.78-
Shares Outstanding27.7721.6922.5622.5622.5622.56
Market Capitalization126.08126.08196.80---

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.040.02
Cost of Goods Sold Incl. D&A0.030.030.030.000.020.00--
Gross Profit-0.03-0.03-0.030.00-0.020.00--
Selling, General and Administrative Excl. Other5.8114.047.0213.706.925.7137.622.12
Research and Development1.312.651.291.250.720.681.001.08
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.83-14.07-7.06-13.70-6.93-5.71-37.58-2.10
Interest Expense0.270.401.171.591.310.240.480.14
Unusual Expense-1.650.06-0.000.310.380.000.000.02
Net Income Before Taxes-4.44-14.24-8.82-15.52-8.62-5.68-38.00-2.25
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-4.44-14.24-8.82-15.52-8.62-5.68-38.00-2.25
Net Income From Continuing Operations-4.44-14.24-8.82-15.52-8.62-5.68-38.00-2.25
Net Income-7.27-14.24-8.82-15.52-8.62-5.68-38.00-2.25
EPS (Recurring)-0.33-0.58-0.38-0.71-0.43-0.30-2.10-0.10
EPS (Basic, Before Extraordinaries)-0.28-0.58-0.38-0.72-0.45-0.30-2.10-0.10
EPS (Diluted)-0.28-0.58-0.38-0.72-0.45-0.30-2.10-0.10
EBITDA-5.81-14.04-7.02-13.70-6.92-5.71-37.58-2.10
Non-Operating Income (Expense)0.000.29-0.590.070.010.270.050.00
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.275.652.739.595.043.5323.07-
Price To Sales Ratio---4,485.102,907.861,132.28--
Operating Margin-------93,965.52-10,487.41
Net Margin-------95,028.72-11,264.91
Shares Outstanding27.7724.8524.1321.6919.4719.0319.0322.56
Market Capitalization126.08117.47159.07198.24173.9667.93250.44336.92

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY
Cash & Short Term Investments0.060.060.030.630.03
Short Term Receivables0.140.150.000.000.00
Inventories0.000.000.000.000.00
Other Current Assets0.440.240.260.100.01
Total Current Assets0.640.450.290.730.03
Net Property, Plant & Equipment0.360.020.000.000.00
Total Investments and Advances0.000.000.000.000.00
Intangible Assets0.500.000.000.000.00
Other Assets1.322.940.970.000.00
Total Assets2.823.421.270.730.03
Short Term Debt Incl. Current Port. of LT Debt6.020.026.610.050.24
Accounts Payable7.113.522.961.340.54
Other Current Liabilities6.905.385.690.911.87
Total Current Liabilities20.048.9215.252.302.65
Long Term Debt0.290.000.000.000.00
Provision for Risks Charges0.000.000.000.000.00
Other Liabilities0.000.000.000.000.00
Total Liabilities20.338.9215.252.302.65
Non-Equity Reserves0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.00
Common Equity-17.51-5.50-13.99-1.58-2.62
Total Shareholders Equity-17.51-5.50-13.99-1.58-2.62
Accumulated Minority Interest0.000.000.000.000.00
Total Equity-17.51-5.50-13.99-1.58-2.62
Total Liabilities & Stockholders Equity2.823.421.270.730.03
Book Value Per Share-0.81-0.24-0.62-0.07-0.12
Tangible Book Value Per Share-0.83-0.24-0.62-0.07-0.12
Full-Time Employees5435-
Price to Book Ratio-9.21-13.53---
Return on Assets-1,991.59-508.20-1,496.55-800.54-
Quick Ratio0.030.050.020.320.01
Current Ratio0.030.050.020.320.01

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY
Net Income-43.02-62.15-11.90-14.92-3.05-3.38
Depreciation0.080.04----
Other Funds (Non Cash)19.2539.616.2011.331.502.32
Funds from Operations-23.69-22.50-5.70-3.59-1.55-1.05
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital3.262.141.491.710.670.66
Cash from Operating Activities-20.44-20.36-4.21-1.88-0.88-0.40
Capital Expenditures-0.50-0.500.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.50-0.500.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Change in Capital Stock32.2617.164.15-0.092.400.00
Repurchase of Common Pref Stock-5.790.000.000.000.000.00
Sale of Common Pref Stock38.0517.164.15-0.092.400.00
Proceedsfrom Stock Options22.9817.164.15-0.092.400.00
Issuance or Reduction of Debt, Net-6.673.700.101.37-0.210.25
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.00-0.700.00
Other Financing Activities Uses0.000.000.000.00-0.700.00
Cash from Financing Activities25.5920.864.251.281.490.25
Net Change in Cash4.65-0.010.03-0.600.61-0.15
Free Cash Flow-20.44-20.36-4.21-1.88-0.88-0.40
Preferred Dividends (Cash Flow)-0.000.000.00--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments6.171.970.140.061.510.13
Short Term Receivables0.140.140.260.140.140.15
Inventories0.000.000.000.000.000.00
Other Current Assets1.271.270.980.440.540.61
Total Current Assets7.583.381.370.642.190.89
Net Property, Plant & Equipment0.300.320.340.360.380.40
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.470.480.490.50--
Other Assets0.951.051.131.321.511.71
Total Assets9.305.233.332.824.082.99
Short Term Debt Incl. Current Port. of LT Debt0.080.070.076.024.770.07
Accounts Payable3.823.882.637.112.143.57
Other Current Liabilities18.3419.5613.586.908.6810.84
Total Current Liabilities22.2423.5116.2920.0415.5914.48
Long Term Debt0.240.250.270.290.310.33
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities22.4823.7616.5620.3315.9014.80
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.001E-060.000.000.000.00
Common Equity-13.17-18.53-13.23-17.51-11.81-11.82
Total Shareholders Equity-13.17-18.53-13.23-17.51-11.81-11.82
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-13.17-18.53-13.23-17.51-11.81-11.82
Total Liabilities & Stockholders Equity9.305.233.332.824.082.99
Book Value Per Share-0.47-0.75-0.55-0.81-0.61-0.62
Tangible Book Value Per Share-0.49-0.76-0.57-0.83-0.61-0.62
Full-Time Employees---5--
Price to Book Ratio-9.21-8.26-8.68-13.63-14.62-7.06
Return on Assets-642.77-1,148.42-656.48-2,173.48--
Quick Ratio0.340.140.080.030.140.06
Current Ratio0.340.140.080.030.140.06

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-4.44-14.24-8.82-15.52-8.62-0.00
Depreciation0.030.030.030.00--
Other Funds (Non Cash)-1.295.923.6410.986.61-1.94
Funds from Operations-5.71-8.29-5.15-4.54-1.96-1.94
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.623.53-1.840.95-3.84-3.37
Cash from Operating Activities-5.09-4.77-6.99-3.59-5.81-5.31
Capital Expenditures0.000.000.00-0.500.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.00-0.500.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Change in Capital Stock9.286.6013.742.643.200.00
Repurchase of Common Pref Stock-5.790.000.000.000.000.00
Sale of Common Pref Stock15.076.6013.742.643.200.00
Proceedsfrom Stock Options15.07-8.4713.742.643.200.00
Issuance or Reduction of Debt, Net0.000.00-6.670.004.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities9.286.607.072.647.200.00
Net Change in Cash4.191.830.08-1.451.39-5.31
Free Cash Flow-5.09-4.77-6.99-3.59-5.81-5.31

Revenue breakdown

Pharmaceutical Preparations2024: 83.00K 2025: 39.99K
United States2024: 83.00K 2025: 39.99K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3034.87%0.9M2.6M208.29K
2026-10-1533.21%0.9M2.6M194.84K
2026-09-3028.70%0.8M2.6M181.63K
2026-09-1519.78%0.5M2.6M170.19K
2026-08-3118.86%0.5M2.5M152.33K
2026-08-1423.91%0.6M2.5M125.49K
2026-07-3130.00%0.6M2.1M91.97K
2026-07-1525.33%0.5M2.1M96.18K
2026-06-3018.36%0.4M2.1M92.07K
2026-06-157.05%0.3M3.8M76.84K
2026-05-296.99%0.3M3.8M66.57K
2026-05-155.16%0.2M4.5M65.19K
2026-04-306.23%0.3M4.4M52.16K
2026-04-158.31%0.4M4.4M51.29K
2026-03-316.82%0.3M4.3M52.47K
2026-03-135.81%0.2M4.1M59.20K
2026-02-275.31%0.2M4.1M61.17K
2026-02-134.51%0.2M4.1M67.99K
2026-01-304.04%0.2M4.3M68.16K
2026-01-153.37%0.1M4.3M63.66K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-094Statement of changes in beneficial ownership of securities2026-11-09SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-038-KCurrent report2026-11-02SEC
2026-10-228-KCurrent report2026-10-16SEC
2026-10-158-KCurrent report2026-10-09SEC
2026-10-153Initial statement of beneficial ownership of securities2026-10-09SEC
2026-09-288-KCurrent report2026-09-28SEC
2026-09-218-KCurrent report2026-09-15SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-178-KCurrent report2026-09-16SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-154Statement of changes in beneficial ownership of securities2026-09-14SEC
2026-09-144Statement of changes in beneficial ownership of securities2026-09-11SEC
2026-09-108-KCurrent report2026-09-08SEC
2026-09-10424B5SEC
2026-08-218-K/A2026-06-27SEC
2026-08-208-KCurrent report2026-08-14SEC
2026-08-204Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-204/A2026-04-10SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-04-09SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-18SEC
2026-08-174Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-138-KCurrent report2026-08-12SEC
2026-08-128-KCurrent report2026-08-12SEC
2026-08-108-KCurrent report2026-08-10SEC
2026-08-1010-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-11269.11K300
2026-100000
2026-09351.42K600
2026-08318.44K600
2026-070000
2026-060000
2026-0541.59K100
2026-04381.97K900
2026-030000
2026-020000
2026-010000
2025-120000
2025-11192.02K300

Institutional holders

Manager% owned
Cinctive Capital Management LP6.20%
VANGUARD CAPITAL MANAGEMENT LLC1.94%
BANK OF AMERICA CORP /DE/0.87%
Westmount Partners, LLC0.76%
BlackRock, Inc.0.69%
GEODE CAPITAL MANAGEMENT, LLC0.56%
VANGUARD FIDUCIARY TRUST CO0.35%
STATE STREET CORP0.17%
NORTHERN TRUST CORP0.14%
Global Retirement Partners, LLC0.10%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.20%
VANGUARD EXTENDED MARKET INDEX FUND0.73%
Fidelity Extended Market Index Fund0.32%
iShares Micro-Cap ETF0.14%
Fidelity Total Market Index Fund0.10%
Fidelity Series Total Market Index Fund0.10%
Fidelity Nasdaq Composite Index Fund0.07%
Ultra-Small Company Market Fund0.03%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND0.02%
1290 VT Micro Cap Portfolio0.01%

OakChart. NTHI. Cached 15 minutes.